As the first first Novartis viral vector production facility in Europe, it significantly expands Novartis' research and ...

Prolific Machines, a biotechnology innovator unlocking unprecedented cellular control with light, appoints Christina Perry as CFO.

Vaccinia virus (VACV) confers cross-protective immunity against variola virus, the causative agent of smallpox, and has therefore been extensively exploited as a preventive vaccine. Despite the global ...

Nanoneedle technology offers the capability to simultaneously quantify titers of true, full viral genomes and a range of ...

T-cell therapy represents a groundbreaking advancement in the field of immuno-oncology. This innovative treatment involves ...

This article examines viral and non-viral vectors in gene therapy, highlighting their mechanisms, advantages, and limitations ...

Amid a broader push to beef up cell and gene therapy manufacturing capacity in Europe, Novartis has opened the doors to a €40 ...

Migrant farmworkers are on the front lines of the H5N1 surge — but deportation fears complicate virus surveillance ...

The state of the art production ultracentrifuges (PUCFs) are limited, especially in rotational speed to approximately 40 krpm by rotary seals, by complexity and virus containment. This prevents PUCFs ...

Cell line development plays a pivotal role in the manufacturing of therapeutic proteins, vaccines and other biologics.

Job cuts in Cambridge and Plainville are the second workforce reduction planned for the facilities in the past three months.

Viralgen and the CTNNB1 Foundation have come together to manufacture an investigational gene therapy designed to treat CTNNB1 ...